HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of March 1, 2021 0.25% Convertible Senior Notes due 2027Halozyme Therapeutics, Inc. • March 1st, 2021 • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of March 1, 2021, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee, registrar, paying agent and conversion agent (the “Trustee”).
